Denali Therapeutics (DNLI) Aandelenoverzicht
Denali Therapeutics Inc., een biofarmaceutisch bedrijf, ontdekt en ontwikkelt therapeutica voor de behandeling van neurodegeneratieve en lysosomale opslagziekten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 0/6 |
DNLI Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Denali Therapeutics Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$21.09 |
| 52 Week Hoogtepunt | US$27.30 |
| 52 Week Laag | US$12.58 |
| Bèta | 1.01 |
| 1 maand verandering | -13.57% |
| 3 maanden verandering | -5.09% |
| 1 Jaar Verandering | 48.63% |
| 3 jaar verandering | -10.45% |
| 5 jaar verandering | -60.08% |
| Verandering sinds IPO | -1.68% |
Recent nieuws en updates
Blood Brain Barrier Platform Risks Will Test This Rare Disease Pipeline Before Potential Upside
Catalysts About Denali Therapeutics Denali Therapeutics develops biologic medicines designed to cross the blood brain barrier for rare genetic and common neurodegenerative diseases. What are the underlying business or industry changes driving this perspective?
Blood Brain Barrier Platform And Rare Disease Pipeline Will Shape Long Term Neurology Potential
Catalysts About Denali Therapeutics Denali Therapeutics develops biologic medicines designed to cross the blood brain barrier for rare genetic and common neurodegenerative diseases. What are the underlying business or industry changes driving this perspective?Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One
Summary Denali Therapeutics (DNLI) is transitioning from a neuroscience platform to a commercial biotech with AVLAYAH, its FDA-approved rare-disease therapy. AVLAYAH's Q2 revenue of $3.6M is projected to triple in Q3, reflecting accelerating patient uptake and payer coverage progress. DNLI's TransportVehicle platform underpins a pipeline spanning enzymes, antibodies, and oligonucleotides, targeting both rare and large neurodegenerative markets. Valuation requires execution: AVLAYAH's commercial ramp and zafinofusp alfa's progress are critical, while Alzheimer’s programs offer significant long-term optionality. Read the full article on Seeking AlphaRecent updates
Blood Brain Barrier Platform Risks Will Test This Rare Disease Pipeline Before Potential Upside
Catalysts About Denali Therapeutics Denali Therapeutics develops biologic medicines designed to cross the blood brain barrier for rare genetic and common neurodegenerative diseases. What are the underlying business or industry changes driving this perspective?Blood Brain Barrier Platform And Rare Disease Pipeline Will Shape Long Term Neurology Potential
Catalysts About Denali Therapeutics Denali Therapeutics develops biologic medicines designed to cross the blood brain barrier for rare genetic and common neurodegenerative diseases. What are the underlying business or industry changes driving this perspective?Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One
Summary Denali Therapeutics (DNLI) is transitioning from a neuroscience platform to a commercial biotech with AVLAYAH, its FDA-approved rare-disease therapy. AVLAYAH's Q2 revenue of $3.6M is projected to triple in Q3, reflecting accelerating patient uptake and payer coverage progress. DNLI's TransportVehicle platform underpins a pipeline spanning enzymes, antibodies, and oligonucleotides, targeting both rare and large neurodegenerative markets. Valuation requires execution: AVLAYAH's commercial ramp and zafinofusp alfa's progress are critical, while Alzheimer’s programs offer significant long-term optionality. Read the full article on Seeking Alpha
Brain Delivery Platform And Rare Disease Portfolio Will Support Long-Term Upside Potential
Catalysts About Denali Therapeutics Denali Therapeutics focuses on biologic medicines engineered to cross the blood brain barrier for rare genetic and common neurodegenerative diseases. What are the underlying business or industry changes driving this perspective?We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Denali Therapeutics: Vast Pipeline, First Approval Up Ahead
Summary Denali Therapeutics' stock has significantly dropped from $100 to $15 since 2021, but the company is now heavily derisked with promising product candidates nearing key milestones. Lead asset DNL310 shows strong biomarker data for Hunter syndrome, with plans for a BLA submission and accelerated approval by Q2 2025. The Biogen partnership for Parkinson’s Disease asset DNL151 includes substantial milestone payments and profit-sharing, highlighting its potential impact. Despite past failures, Denali's extensive pipeline and solid financial runway make it a compelling buy at current low stock prices. Read the full article on Seeking AlphaDenali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
Summary Denali Therapeutics Inc.'s DNL343 failed to meet the primary endpoint in the phase 2/3 HEALY ALS trial, but potential biomarker analyses in 2025 may offer a path forward. Despite the trial setback in ALS, Denali's stock remains stable due to continued pre-specified analyses expected in late 2025. BLA filing of tividenofusp alfa for the treatment of patients with MPS II remains on track under the Accelerated Approval Pathway Program in early 2025. Financially, Denali has $1.28 billion in cash but may need additional funding in 2025, posing a risk of shareholder dilution. Read the full article on Seeking AlphaWe're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology
Summary Denali Therapeutics' proprietary Transport Vehicle technology enables drug delivery across the blood-brain barrier, targeting neurodegenerative diseases. DNL310, targeting MPS II, and DNL343 for ALS are key drug candidates with potential, though competition is significant. The company’s $500 million capital raise supports its aggressive R&D investment, providing a runway for developing its pipeline. Despite its promising platform, DNLI still has a relatively high cash burn and regulatory hurdles before achieving drug approval. Due to Denali's high-risk, long-term biotech development, I deem DNLI a DCA "buy" for investors who understand the inherent risks. Read the full article on Seeking AlphaCompanies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%
Denali Therapeutics Inc. ( NASDAQ:DNLI ) shareholders would be excited to see that the share price has had a great...Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data
Summary Denali Therapeutics Inc.'s DNL-310 is currently being explored in an ongoing phase 2/3 COMPASS study for treatment of patients with MPS II; Enrollment completion expected in 2024. Denali is in talks with CDER division of FDA to seek for Accelerated Approval pathway for DNL-310 for the treatment of patients with MPS II. Biomarker and safety data from a phase 1/2 study, using DNL-126 for the treatment of patients with MPS IIIA, expected end of 2024. Another promising program from the pipeline is the development of DNL-343, which is being advanced in the phase 2/3 HEALEY ALS Platform trial for treatment of patients with amyotrophic lateral sclerosis. Read the full article on Seeking AlphaAn Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Denali Therapeutics fair value estimate is US$30.71 Denali...Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Those holding Denali Therapeutics Inc. ( NASDAQ:DNLI ) shares would be relieved that the share price has rebounded 25...Denali: Leveraging Transport Vehicle Technology For Neurological Gains
Summary Denali's stock performance has been flat despite the biotech sector's 20% rise; recently raised $500 million in a PIPE. ALS trial failure with partner Sanofi pressured stock; Denali's focus is on transport vehicle (TV) technology and BBB crossing. Denali boasts a strong financial position with $1.53 billion in cash, extending operational runway significantly. Recommends "buy" based on Denali's innovative TV technology, financial health, and potential in neurological disorders despite biotech risks. Read the full article on Seeking AlphaCompanies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet
Denali Therapeutics Inc.'s ( NASDAQ:DNLI ) price-to-sales (or "P/S") ratio of 7x might make it look like a buy right...We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Rendement voor aandeelhouders
| DNLI | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -5.3% | -5.2% | -0.9% |
| 1Y | 48.6% | 37.6% | 14.2% |
Rendement versus industrie: DNLI overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 37.6 % opleverde.
Rendement versus markt: DNLI overtrof de US markt, die het afgelopen jaar een rendement opleverde van 14.2 %.
Prijsvolatiliteit
| DNLI volatility | |
|---|---|
| DNLI Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: DNLI heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van DNLI is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2013 | 507 | Ryan Watts | www.denalitherapeutics.com |
Denali Therapeutics Inc., een biofarmaceutisch bedrijf, ontdekt en ontwikkelt therapeutica voor de behandeling van neurodegeneratieve en lysosomale opslagziekten. Het bedrijf ontwikkelt het Eclitasertib (SAR443122/DNL758) RIPK1-remmerprogramma voor perifere ontstekingsziekten; het BIIB122/DNL151 LRRK2-remmerprogramma voor de ziekte van Parkinson; TAK-594/DNL593-programma voor frontotemporale dementie-granuline; DNL126-programma voor MPS IIIA (Sanfilippo Syndroom A); en DNL310 Tividenofusp alfa, een enzymvervangingsprogramma voor MPS II (Hunter Syndroom). De Enzyme TransportVehicle (TV)-programma's van het bedrijf omvatten DNL952 voor de behandeling van de ziekte van Pompe, DNL111 voor de ziekten van Parkinson en Gaucher en DNL622 voor het Hurler-syndroom (MPS I).
Denali Therapeutics Inc. Samenvatting
| DNLI fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$3.37b |
| Inkomsten(TTM) | -US$511.45m |
| Inkomsten(TTM) | US$3.60m |
Is DNLI overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| DNLI resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$3.60m |
| Kosten van inkomsten | US$400.81m |
| Brutowinst | -US$397.21m |
| Overige uitgaven | US$114.24m |
| Inkomsten | -US$511.45m |
Laatst gerapporteerde inkomsten
Jun 30, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -3.20 |
| Brutomarge | -11,021.34% |
| Nettowinstmarge | -14,191.20% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde DNLI op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/13 07:37 |
| Aandelenkoers aan het einde van de dag | 2026/09/11 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Denali Therapeutics Inc. wordt gevolgd door 33 analisten. 19 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| null null | Baird |
| Joel Beatty | Baird |
| Charles Moore | Baird |